Orviglance

A public-source reconstruction of the Orviglance FDA evidence pathway, examining why statistically positive Phase 3 results did not, by themselves, establish decision-ready regulatory evidence. The analysis traces how reader interpretation, endpoint construction, and evidentiary assumptions shape the transition from scientific observation to regulatory decision support.